Parker Institute for Cancer Immunotherapy (PICI), shared on LinkedIn:
“Cancer vaccines are moving from a promising idea to a rapidly advancing area of cancer treatment, with new clinical trial results and personalized approaches bringing the field closer to changing how we treat the disease.
In a feature for the New York Post, Allie Yang explores what’s next for cancer vaccines and interviews cancer vaccine recipients, like Molly Hones and Ariana Nakata, who are already seeing the potential firsthand.
Kristen Dahlgren, Chief External Affairs Officer at PICI, shares why this could be a defining moment for cancer patients:
‘I think we’re about to change things profoundly for cancer patients.’
The article also features Parker Institute researchers Dr. Catherine Wu and Bhardwaj Nina, who share their perspectives on the science and their work to accelerate progress and bring the promise of cancer immunotherapy to more patients.”
Read the full post.
You may also be interested in: The Big Questions in Cancer Immunotherapy: Are Personalized Cancer Vaccines Finally Ready to Deliver?
